| Autor: |
Price, D., Park, H.S., Yoon, D., Lee, H.Y., Wan Yau Ming, S., Van Boven, J.F. |
| Přispěvatelé: |
Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), Groningen Research Institute for Asthma and COPD (GRIAC) |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Respirology, 21. Wiley |
| ISSN: |
1323-7799 |
| Popis: |
Background and Aims: In Korea, the majority of asthma patients are prescribed dry powder inhalers (DPIs). Patients prescribed inhaled corticosteroid/ long-acting beta agonists (ICS/LABA) may benefit from switching from a DPI to a pressurized Metered Dose Inhaler (pMDI), such as formoterol/fluticasone. The primary aim of this study was to evaluate the 'switch success' of changing asthma patients from ICS/LABA DPIs to formoterol/ fluticasone pMDI in a real-world population in Korea. Secondly, we aim to determine if there are any differences in key clinical parameters (e.g. exacerbations, blood eosinophil counts) between patients who switch inhaler and those who continue on the same inhaler. Methods: Historical cohort database study with baseline and outcome period designed to evaluate the proportion of asthma patients that continue to collect prescriptions of formoterol/fluticasone after initial prescription. Data source is the inhouse clinical asthma database of the Ajou University Hospital (Suwon, Korea). Switch success is considered as >70% of the population maintaining their treatment at least 6 months after the switch. The study is powered for the 'switch success' of asthma patients changing their therapy to and continuing on formoterol/fluticasone from existing ICS/LABA DPIs. Both patients switching to formoterol/ fluticasone and those remaining on ICS/LABA DPIs will be fully characterised during baseline period. If sufficient numbers are available (sample size required: 163 per cohort), for all of additional outcomes, the outcome year will be compared to the baseline year within the switch cohort. The additional outcomes include: % non-exacerbating patients of 'switch' cohort at 1 year, compared to baseline, exacerbation rates, asthma control, reliever use, side effects and total ICS use. Results: The protocol has been submitted to ENCePP. Study results (expected end 2016) will provide insights in the real-life effects of switching inhalers. Conclusions: Outcomes of this study are expected to lead to hands-on recommendations for optimal, cost-effective, treatment options for asthma management. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text